Vitamin D and diabetic nephropathy

被引:0
作者
Yan Chun Li
机构
[1] The University of Chicago,Department of Medicine
来源
Current Diabetes Reports | 2008年 / 8卷
关键词
Renin; Diabetic Nephropathy; Aliskiren; Paricalcitol; Renin Inhibitor Aliskiren;
D O I
暂无
中图分类号
学科分类号
摘要
Diabetic nephropathy (DN) is the most common renal complication of diabetes mellitus and a leading cause of end-stage renal disease. The renin-angiotensin system (RAS) is a major mediator of progressive renal injury in DN, and RAS inhibitors have been used as the mainstay treatment for DN. One major problem limiting the efficacy of the RAS inhibitors is the compensatory renin increase caused by disruption of renin feedback inhibition. Vitamin D negatively regulates the RAS by suppressing renin expression and thus plays a renoprotective role in DN. Diabetic vitamin D receptor-null mutant mice develop more severe renal injuries because of more robust RAS activation. Combination therapy with an RAS inhibitor and a vitamin D analogue markedly ameliorates renal injuries due to blockade of the compensatory renin increase by the analogue. These most recent data demonstrate that vitamin D and its analogues have renoprotective and therapeutic potentials in DN through targeting the RAS.
引用
收藏
页码:464 / 469
页数:5
相关论文
共 140 条
[1]  
Cooper M.E.(1998)Pathogenesis, prevention, and treatment of diabetic nephropathy Lancet 352 213-219
[2]  
Brownlee M.(2001)Biochemistry and molecular cell biology of diabetic complications Nature 414 813-820
[3]  
Carey R.M.(2003)The intrarenal renin-angiotensin system and diabetic nephropathy Trends Endocrinol Metab 14 274-281
[4]  
Siragy H.M.(2004)Mediators of diabetic renal disease: the case for TGF-beta as the major mediator J Am Soc Nephrol 15 S55-S57
[5]  
Ziyadeh F.N.(1993)The role of macrophages in diabetic glomerulosclerosis Am J Kidney Dis 21 480-485
[6]  
Furuta T.(2003)Minireview: overview of the reninangiotensin system-an endocrine and paracrine system Endocrinology 144 2179-2183
[7]  
Saito T.(2006)Physiology of local renin-angiotensin systems Physiol Rev 86 747-803
[8]  
Ootaka T.(2000)Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients Kidney Int 57 590-600
[9]  
Lavoie J.L.(2001)Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851-860
[10]  
Sigmund C.D.(2001)The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870-878